Biotech Values

[dewophile]

Ascribing negative value to a biotech pipeline is nothing new or uncommon, as you know. (Wasn’t there a table of biotechs trading below cash at one time). It’s not hard to waste money in drug development. What is surprising though is a company like ENTA not getting any benefit of the doubt in light of their track record.